Benitec Biopharma Inc.

BNTC · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders2.5%

Institutions100.5%

Public / Other

Income Statement

	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	$0	$75000	$73000	$59000	$97000
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$41.77M	-$22.49M	-$19.08M	-$17.85M	-$13.60M	-$8.28M
Operating income as a percentage of revenue.	–	–	-25441.3%	-24457.5%	-23044.1%	-8537.1%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$37.92M	-$21.75M	-$19.56M	-$18.21M	-$13.88M	-$8.27M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.00	$-5.51	$-14.12	$-2.23	$-3.23	$-8.10
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.00	$-5.51	$-14.12	$-2.23	–	–

Balance Sheet

	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30
Cash and highly liquid short-term investments the company can access almost immediately.	$97.70M	–	$2.50M	$4.10M	$19.77M	$9.80M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$99.59M	$52.21M	$4.46M	$5.97M	$21.38M	$11.59M
Everything the company owes — debt, unpaid bills, and other obligations.	$2.30M	$4.96M	$4.26M	$3.09M	$1.37M	$1.35M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$97.30M	$47.25M	$202000	$2.88M	$20.01M	$10.24M

Cash Flow Statement

	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$23.60M	-$19.40M	-$18.00M	-$15.90M	-$12.80M	-$7.54M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$18000	$179000	$1000	$13000	$221000	$95000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$23.62M	-$19.58M	-$18.00M	-$15.91M	-$13.02M	-$7.63M

	You	Peer avg
Revenue Growth	–	-89.5%
ROE	-29.6%	-59.5%

Benitec Biopharma Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison